Anti-Parkinson's disease drugs and pharmacogenetic considerations

ISSN： 1742-5255

Source： Expert Opinion on Drug Metabolism and Toxicology, Vol.9, Iss.7, 2013-07, pp. : 859-874

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging analgesic drugs for Parkinson's disease

By Perez-Lloret Santiago Rey María Verónica Dellapina Estelle Pellaprat Jean Brefel-Courbon Christine Rascol Olivier

Expert Opinion on Emerging Drugs, Vol. 17, Iss. 2, 2012-06 ,pp. : 157-171

Informa Healthcare

Access to resources Recommend Favorite

Pharmacoeconomic considerations of treating patients with advanced Parkinson's disease

By Reese Jens P Dams Judith Winter Yaroslav Balzer-Geldsetzer Monika Oertel Wolfgang H Dodel Richard

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 7, 2012-05 ,pp. : 939-958

Informa Healthcare

Access to resources Recommend Favorite

Management of Parkinson's Disease Dementia: Practical Considerations

By Rongve Arvid Aarsland Dag

Drugs & Aging, Vol. 23, Iss. 10, 2006-01 ,pp. : 807-822

Adis International

Access to resources Recommend Favorite

Treatment of Psychosis in Parkinsons Disease: Safety Considerations

By Fernandez H.H. Trieschmann M.E. Friedman J.H.

Drug Safety, Vol. 26, Iss. 9, 2003-01 ,pp. : 643-659

Adis International

Access to resources Recommend Favorite

Pharmacogenetic Considerations in the Elderly Patient

By Bright David R. Calinski Diane M. Kisor David F.

The Consultant Pharmacist, Vol. 30, Iss. 4, 2015-04 ,pp. : 228-239

American Society of Consultant Pharmacists

Access to resources Recommend Favorite